Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

Ascentage Pharma reported a 93% YoY increase in Olverembatinib sales to $30.3 million in H1 2025, driven by expanded NRDL coverage. The company also commenced commercial sales of Lisaftoclax in China and completed a top-up placement in July, raising $190.1 million in net proceeds. Nine registrational clinical trials are ongoing, including three cleared by the FDA.